Top Wall Street Stories: Connecture, Inc. (NASDAQ:CNXR), INTL FCStone Inc. (NASDAQ:INTL), USG Corporation (NYSE:USG), IntelliPharmaCeutics International Inc. (NASDAQ:IPCI)

Connecture, Inc. (NASDAQ:CNXR) shares increased 8.43% in last trading session and ended the day at $11.57. CNXR Gross Margin is 42.60% and its return on assets is -13.00%. Connecture, Inc. (NASDAQ:CNXR) quarterly performance is 3.77%. Zacks downgraded shares of Connecture, Inc. (NASDAQ:CNXR) from a hold rating to a sell rating in a research note released on Tuesday morning.

On 10 July, INTL FCStone Inc. (NASDAQ:INTL) shares increased 1.16% and was closed at $33.22. INTL EPS growth in last 5 year was -1.70%. INTL FCStone Inc. (NASDAQ:INTL) year to date (YTD) performance is 61.50%.INTL FCStone Inc. (NASDAQ:INTL) announced that the investment banking group of its Broker-Dealer Division acted as the exclusive financial adviser, together with Hyundai Securities of South Korea, to Hyundai Merchant Marine Co., Ltd (“HMM”) in arranging $155 million of debt facilities for Hyundai Merchant Marine (America), Inc. (“HMMA”), a wholly owned subsidiary of HMM, with funds and accounts managed by affiliates of Apollo Capital Management, LLC (“Apollo”)

USG Corporation (NYSE:USG) ended the last trading day at $26.98. Company weekly volatility is calculated as 2.78% and price to cash ratio as 18.33. USG Corporation (NYSE:USG) showed a weekly performance of -2.77%. USG Corporation (NYSE:USG) said that, it will hold a conference call and webcast to discuss second quarter 2015 results on Thursday, July 23, 2015, at 9:00 a.m. Eastern time (8:00 a.m. Central time).

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) shares increased 0.87% in last trading session and ended the day at $3.48. IPCI return on assets is -53.40%. IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) quarterly performance is 25.18%. On 8 July, IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) advised that the United States Food and Drug Administration (“FDA”) has indicated to the Company that it has rescinded its previous requirement that the Company meet newly-imposed conditions for bioequivalence prior to receiving final approval for the Company’s tentatively-approved strengths of its generic Focalin XR® (dexmethylphenidate hydrochloride extended-release) capsules (the “Product”). The strengths affected include 5 mg, 10 mg, 20 mg and 40 mg. The already-approved 15 mg and 30 mg strengths now in the market are not affected.

Leave a Reply

Your email address will not be published. Required fields are marked *